文献速递糖尿病

妊娠期糖尿病预防和治疗研究的核心结局集

A core outcome set for studies of gestational diabetes mellitus prevention and treatment.
PubMed 文献 · Diabetologia · 2020-03-20

该研究通过系统综述和三轮电子德尔菲法及面对面共识会议,为评估妊娠期糖尿病(GDM)预防或治疗干预的试验制定核心结局集(COS)。系统综述识别了74个GDM预防结局和116个治疗结局,最终共识纳入14个结局(6个母亲结局和8个新生儿结局),以促进未来试验的结局比较与合并。

要点

  • 最终核心结局集包含6个母亲结局和8个新生儿结局。
  • 母亲结局包括GDM诊断、干预依从性、妊娠期高血压疾病等。
  • 新生儿结局包括出生体重、大于胎龄儿、小于胎龄儿、早产等。

核心结论

  • 该核心结局集将促使未来GDM预防和治疗试验测量对利益相关者重要的相似结局,并促进这些研究的比较与合并。

研究设计与样本

  • 系统综述识别既往报告的结局,并通过三轮电子德尔菲研究由利益相关者(包括患者代表、研究人员和临床医生)进行优先排序,最终在面对面共识会议上定稿核心结局集。
  • 第一轮电子德尔菲研究由173名利益相关者完成,其中70%(121/173)完成第二轮,第二轮应答者中84%(102/121)完成第三轮。

主要发现

  • 系统综述识别了74个GDM预防结局和116个GDM治疗结局,并在电子德尔菲研究第一轮中呈现给利益相关者。
  • 共识会议讨论了22个GDM预防结局和30个GDM治疗结局,因预防与治疗结局显著重叠,共识会议利益相关者同意制定单一预防/治疗核心结局集。
  • 最终核心结局集纳入14个结局,包括6个母亲结局和8个新生儿结局。
  • 母亲结局为GDM诊断、干预依从性、妊娠期高血压疾病、高血糖药物治疗的需求和类型、妊娠期体重增长和分娩方式。
  • 新生儿结局为出生体重、大于胎龄儿、小于胎龄儿、出生时胎龄、早产、新生儿低血糖、新生儿死亡和死产。

关键数值与推荐

  • 最终核心结局集包含14个结局:6个母亲结局和8个新生儿结局。
  • 母亲结局:GDM诊断、干预依从性、妊娠期高血压疾病、高血糖药物治疗的需求和类型、妊娠期体重增长、分娩方式。
  • 新生儿结局:出生体重、大于胎龄儿、小于胎龄儿、出生时胎龄、早产、新生儿低血糖、新生儿死亡、死产。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of this systematic review was to develop core outcome sets (COSs) for trials evaluating interventions for the prevention or treatment of gestational diabetes mellitus (GDM). METHODS: We identified previously reported outcomes through a systematic review of the literature. These outcomes were presented to key stakeholders (including patient representatives, researchers and clinicians) for prioritisation using a three-round, e-Delphi study. A priori consensus criteria informed which outcomes were brought forward for discussion at a face-to-face consensus meeting where the COS was finalised. RESULTS: Our review identified 74 GDM prevention and 116 GDM treatment outcomes, which were presented to stakeholders in round 1 of the e-Delphi study. Round 1 was completed by 173 stakeholders, 70% (121/173) of whom went on to complete round 2; 84% (102/121) of round 2 responders completed round 3. Twenty-two GDM prevention outcomes and 30 GDM treatment outcomes were discussed at the consensus meeting. Owing to significant overlap between included prevention and treatment outcomes, consensus meeting stakeholders agreed to develop a single prevention/treatment COS. Fourteen outcomes were included in the final COS. These consisted of six maternal outcomes (GDM diagnosis, adherence to the intervention, hypertensive disorders of pregnancy, requirement and type of pharmacological therapy for hyperglycaemia, gestational weight gain and mode of birth) and eight neonatal outcomes (birthweight, large for gestational age, small for gestational age, gestational age at birth, preterm birth, neonatal hypoglycaemia, neonatal death and stillbirth). CONCLUSIONS/INTERPRETATION: This COS will enable future GDM prevention and treatment trials to measure similar outcomes that matter to stakeholders and facilitate comparison and combination of these studies. TRIAL REGISTRATION: This study was registered prospectively with the Core Outcome Measures in Effectiveness Trials (COMET) database: http://www.comet-initiative.org/studies/details/686/.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Egan AM, Bogdanet D, Griffin TP, et al. A core outcome set for studies of gestational diabetes mellitus prevention and treatment. Diabetologia. 2020. PMID: 32193573. doi:10.1007/s00125-020-05123-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。